Status:
COMPLETED
Safety and Efficacy Study of KAI-9803 to Treat Subjects With ST Elevation Myocardial Infarction [Heart Attack]
Lead Sponsor:
KAI Pharmaceuticals
Collaborating Sponsors:
Bristol-Myers Squibb
The Cleveland Clinic
Conditions:
Myocardial Infarction
Cardiovascular Diseases
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
The purpose of this study is to determine whether KAI-9803 is safe and effective in reducing infarct size in subjects with ST elevation myocardial infarction (heart attack) undergoing a percutaneous c...
Eligibility Criteria
Inclusion
- Acute STEMI and has a planned emergent primary PCI procedure
- Continuous symptoms of cardiac ischemia and present to the primary PCI facility within 6 hours of symptom onset
Exclusion
- Persistent systolic blood pressure \< 90 mm Hg
Key Trial Info
Start Date :
November 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 1 2011
Estimated Enrollment :
1180 Patients enrolled
Trial Details
Trial ID
NCT00785954
Start Date
November 1 2008
End Date
May 1 2011
Last Update
September 2 2011
Active Locations (126)
Enter a location and click search to find clinical trials sorted by distance.
1
Huntsville, Alabama, United States, 35801
2
Escondido, California, United States, 92025
3
Torrance, California, United States, 90509
4
Tampa, Florida, United States, 33613